Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2012
12/13/2012US20120316106 Synergistic antibiotic combinations and derivatives
12/13/2012US20120316066 Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex
12/13/2012US20120315634 Distinguishing pca3 messenger rna species in benign and malignant prostate tissues
12/13/2012US20120315345 Functional food and pharmaceutical compositions for anti-obesity comprising capsanthin and fatty-acyl ester of capsanthin having anti-adipogenic activity
12/13/2012US20120315344 Cosmetic Compositions and Methods for Using Same to Improve the Aesthetic Appearance of Skin
12/13/2012US20120315341 Method for treating an inflammation or lesion caused by a virus
12/13/2012US20120315339 Nitrooxy alkanoic acids and derivatives thereof in feed for reducing methane emission in ruminants, and/or to improve ruminant performance
12/13/2012US20120315337 Multiparticulate 5-htp compositions and related methods
12/13/2012US20120315336 Injectable nanoparticulate olanzapine formulations
12/13/2012US20120315335 Self-assembling nanoparticle drug delivery system
12/13/2012US20120315334 Pharmaceutical or neutraceutical formulation
12/13/2012US20120315331 Pharmaceutical composition for the treatment of acute disorders
12/13/2012US20120315330 Pharmaceutical composition for the treatment of acute disorders
12/13/2012US20120315329 Siloxane surface-modified hydrogel and hydrogel microparticle compositions
12/13/2012US20120315326 Multiparticulate l-carnitine compositions and related methods
12/13/2012US20120315324 Exosomal compositions and methods for the treatment of disease
12/13/2012US20120315320 Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensivity and radiosensitivity in tumor or cancer cells
12/13/2012US20120315318 Transdermal preparation
12/13/2012US20120315315 Foam Formulations Containing at Least One Triterpenoid
12/13/2012US20120315311 Antiviral composition and method of use
12/13/2012US20120315309 Modified pectins, compositions and methods related thereto
12/13/2012US20120315306 Pharmaceutical composition and preparation for oral administration
12/13/2012US20120315304 Sensitization of immune system against haptenized melanoma antigens
12/13/2012US20120315303 Methods and intravascular treatment devices using paclitaxel for treatment of atherosclerosis
12/13/2012US20120315302 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
12/13/2012US20120315300 Insertable medical devices with a porous bed for delivering nano-carriers to a target site and methods of preparing the same
12/13/2012US20120315299 Pharmaceutical composition for intracellular acidification with cis-urocanic acid
12/13/2012US20120315298 Local treatment of neurofibromas
12/13/2012US20120315296 Lentiviral gene transfer vectors and their medicinal applications
12/13/2012US20120315291 Purine derivatives and their pharmaceutical uses
12/13/2012US20120315289 Non-polysaccharide constituent of genus Dendrobium, usage for the non-polysaccharide constituent of genus Dendrobium and extracting method thereof
12/13/2012US20120315284 Composition for enhancing trail sensitivity comprising inhibitors for expression or activity of tip41 as a target gene of trail sensitizer
12/13/2012US20120315283 Methods of promoting tissue growth and tissue regeneration
12/13/2012US20120315281 Treatment of renal injury
12/13/2012US20120315265 Hydrogel-forming polymer, and preparation process and uses thereof
12/13/2012US20120315264 Zwitterionic immunomodulators for the teatment of asthma and allergy
12/13/2012US20120315256 Use of transforming growth factor - beta 1 (tgf-b1) inhibitor peptides for the treatment of corneal fibrosis and/or haze
12/13/2012US20120315255 Hepatocyte Based Insulin Gene Therapy For Diabetes
12/13/2012US20120315253 Methods to enhance delivery and engraftment of stem cells including the identification of specific prostagandin e2 receptors
12/13/2012US20120315247 Compounds comprising a spiro-ring and methods of use
12/13/2012US20120315244 Methods for Modulation of Autophagy Through the Modulation of Autophagy-Inhibiting Gene Products
12/13/2012US20120315239 Zwitterionic polymer bioconjugates and related methods
12/13/2012US20120315234 Composition for hair and body application
12/13/2012US20120315233 Anthranillic acid amides and derivatives thereof as cosmetic and pharmaceutical active compounds
12/13/2012US20120315223 Compositions for oral use and methods for treating the oral mucosa, lips, and perioral regions
12/13/2012US20120315219 Drug Delivery Coating For Use With A Stent
12/13/2012US20120315217 Inverse agonists and neutral antagonists for the tsh receptor
12/13/2012US20120312312 Solid oral sensorial products including stain inhibitor
12/13/2012DE102011106065A1 Pharmazeutisches Präparat Pharmaceutical preparation
12/13/2012DE102011077393A1 Antiinfektives Mittel Antiinfective agents
12/13/2012DE102011077082A1 Verwendung von Epsilon-Polylysin zur Verbesserung der Wasserfestigkeitkosmetischer oder dermatologischer Formulierungen Use of epsilon-polylysine to improve the Wasserfestigkeitkosmetischer or dermatological formulations
12/13/2012DE102011077077A1 Active substance combination useful as a deodorizing agent in cosmetic deodorants, and as active ingredient in anti-dandruff shampoos, comprises epsilon-polylysine and terpene
12/13/2012DE102011077075A1 Active agent combination, useful in cosmetic preparation, and as an active substance against bacteria, fungus and virus and as deodorant or antiperspirant, comprises epsilon-polylysine and alkylglucosides
12/13/2012DE102011077071A1 Active substance combination useful as a deodorizing agent in cosmetic deodorants, and as active ingredient in anti-dandruff shampoos, comprises epsilon-polylysine and climbazole
12/13/2012DE102011077070A1 Active agent combination, useful e.g. as an active substance against bacteria, fungus and virus and as deodorant or antiperspirant, comprises epsilon-polylysine and aromatic esters with terpene structure
12/13/2012DE102011077067A1 Active substance combination useful e.g. in cosmetic deodorants, comprises epsilon-polylysine and an aromatic aldehyde e.g. hexyl cinnamaldehyde
12/13/2012DE102011077063A1 Active substance combination useful in cosmetic composition, preferably cosmetic deodorants, comprises epsilon polylysine, and an aromatic alcohol
12/13/2012DE102011077055A1 Active agent combination, useful in cosmetic preparation and as an active substance against bacteria, fungus and virus, and as deodorant or antiperspirant active agent, comprises epsilon-polylysine and aromatic esters
12/13/2012DE102011077052A1 Verwendung von epsilon-Poly-L-Lysin zur Erhöhung der Bioverfügbarkeit antimikrobieller Peptide in menschlicher Haut. Use of epsilon-poly-L-lysine to increase the bioavailability of antimicrobial peptides in human skin.
12/13/2012DE102011077046A1 Active substance combination useful as a deodorizing agent in cosmetic deodorants, and as active ingredient in anti-dandruff shampoos, comprises epsilon-polylysine and piroctone olamine
12/13/2012DE102011077040A1 Wirkstoffkombinationen aus å-Polylysin (Epsilon-Polylysin) und einem oder mehrerenethoxylierten und/oder propoxylierten Alkanolen Active substance combinations of A-polylysine (epsilon-polylysine) and one or mehrerenethoxylierten and / or propoxylated alkanols
12/13/2012CA2838984A1 Methods for modulating kallikrein (klkb1) expression
12/13/2012CA2838885A1 Pyrimido[4,5-d]pyrimidinyl compounds, pharmaceutical compositions and use thereof
12/13/2012CA2838876A1 Compositions and methods for treating, controlling, reducing, or ameliorating inflammatory pain
12/13/2012CA2838844A1 Uses of histone acetyltransferase activators
12/13/2012CA2838777A1 Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
12/13/2012CA2838604A1 Metal chelating compositions and methods for controlling the growth or activities of a living cell or organism
12/13/2012CA2838589A1 Edible oral strip or wafer dosage form containing ion exchange resin for taste masking
12/13/2012CA2838435A1 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
12/13/2012CA2838401A1 New taccalonolide microtubule stabilizers
12/13/2012CA2838387A1 Use of metallocene compounds for cancer treatment
12/13/2012CA2838275A1 Methods for inhibiting muscle atrophy
12/13/2012CA2838257A1 [1,2,4]thiadiazine 1,1-dioxide compounds for lowering serum uric acid
12/13/2012CA2838110A1 Skin treatments containing pyrroloquinoline quinone (pqq) esters and methods of preparation and use thereof
12/13/2012CA2838069A1 Lipid nanoparticle compositions and methods for mrna delivery
12/13/2012CA2838063A1 Cleavable lipids
12/13/2012CA2838031A1 Dry powder inhaler compositions comprising umeclidinium
12/13/2012CA2838030A1 Combination comprising umeclidinium and a corticosteroid
12/13/2012CA2838029A1 Heterocyclic sulfonamide derivatives
12/13/2012CA2837979A1 Macromolecules
12/13/2012CA2837901A1 Method for the synthesis of porphyrin-phospholipid conjugates
12/13/2012CA2837797A1 [1,3]oxazines
12/13/2012CA2837703A1 Pharmaceutical composition comprising amide derivative inhibiting the growth of cancer cells and non-metallic salt lubricant
12/13/2012CA2837563A1 Methods and compositions for treating brain cancer
12/13/2012CA2837560A1 Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
12/13/2012CA2837255A1 Pyrazole derivatives
12/13/2012CA2837252A1 Halogen-alkyl-1,3 oxazines as bace1 and/or bace2 inhibitors
12/13/2012CA2837242A1 Method of treating dengue fever
12/13/2012CA2837146A1 Benzocycloheptene acetic acids
12/13/2012CA2837101A1 Compounds for targeting drug delivery and enhancing sirna activity
12/13/2012CA2836925A1 Retinoid-liposomes for enhancing modulation of hsp47 expression
12/13/2012CA2836851A1 Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors
12/13/2012CA2836728A1 5-carbamoyl-adamantan-2-yl amide derivatives, pharmaceutically acceptable salts thereof and preparation process thereof
12/13/2012CA2836487A1 Novel compounds as modulators of gpr-119
12/13/2012CA2836227A1 Substituted pyridopyrazines as novel syk inhibitors
12/13/2012CA2835753A1 An edible composition
12/13/2012CA2835745A1 Pyridin - 2 - amides useful as cb2 agonists
12/13/2012CA2835293A1 Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
12/13/2012CA2834675A1 Substituted benzamide derivatives
12/13/2012CA2834610A1 Rna interference mediated inhibition of isocitrate dehydrogenase (idh1) gene expression
1 ... 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 ... 7860